China's Second Domestic Heart Valve Breakthrough: A New Lifeline for 300,000 Complex Congenital Heart Disease Patients

For patients with complex congenital heart disease, the words they fear most are "open your chest again." Tetralogy of Fallot, the most common cyanotic congenital heart defect in newborns, can be surgically corrected in infancy. But the transannular patch used in repair almost inevitably leaves pulmonary valve regurgitation. Over time, the right ventricle dilates, function declines, and patients return to the operating room for valve replacement. Many undergo two to four chest openings in their lifetime.

The patient pool is substantial. According to the China Cardiovascular Health and Disease Report 2025, there were 363,000 congenital heart disease hospitalizations nationwide in 2024, with adults accounting for 76.5%. Balance Medical, citing the 2025 Cardiovascular Surgery White Paper, estimates that approximately 300,000 complex congenital heart disease post-surgical adult patients have accumulated in China over the past 15 years.

Transcatheter pulmonary valve replacement (TPVR) was supposed to offer these patients an escape from repeated sternotomies. The procedure delivers a valve through the femoral vein, avoiding open-chest surgery. Medtronic, Edwards, and Venus Medical's products have received approval, and the 2020 ESC guidelines list TPVR as a Class I recommendation for select patients. But a harsher reality persists: a significant portion of these 300,000 patients cannot undergo even minimally invasive TPVR.

According to Balance Medical's disclosure, these patients typically present with five types of pulmonary artery deformities—aneurysmal dilation, short pyramid shape, upper-wide-lower-narrow configurations, and others. Existing TPVR products' stent designs only accommodate patients whose anatomy closely matches the device form. The company estimates that current products fit only 20-30% of candidates. For the majority, minimally invasive replacement remains out of reach. They must continue undergoing open-chest surgery.

Reshape First, Then Implant: Making the Impossible Possible

On October 9, Balance Medical's transcatheter pulmonary valve system received innovative channel approval from the National Medical Products Administration (NMPA), becoming China's second TPVR product. The registration clinical data are compelling: a prospective cohort study at Guangdong Provincial People's Hospital from 2021 to 2024 enrolled 38 cases, with all surgeries successful. Median follow-up was 24 months, with zero deaths and zero reinterventions. The 36-month major adverse event-free rate reached 87.2%.

Balance Medical's approach differs fundamentally from competitors. While others attempt to match different stent configurations to deformed pulmonary arteries—proceeding when anatomy fits, abandoning when it doesn't—Balance Medical reverses the logic: first make a small incision, reshape the deformed pulmonary artery to near-normal morphology under direct visualization while the heart continues beating, then implant a uniform valve. Regardless of pulmonary artery deformity type, surgeons can reshape first, then implant. This is what Balance Medical calls the "all-comer" approach.

The strategy directly addresses the challenge of "super-large dilation and complex anatomy that cannot be anchored." A case from Union Hospital of Huazhong University of Science and Technology illustrates the point: a 32-year-old patient with pulmonary artery trunk diameter dilated to 38-45mm had no anchoring position for transfemoral interventional valves. Surgeons used Balance Medical's Salus interventional pulmonary valve, performing pulmonary artery ring annuloplasty first, then implanting a 32# valve. Post-operatively, there was no paravalvular leak and no central regurgitation.

What transfemoral approaches cannot do, Balance Medical can.

The company has also bet on durability. TPVR patients are typically adolescents, with valve longevity requirements far exceeding those of elderly TAVR patients. Balance Medical uses a patented sewing technique that, for the first time on a transcatheter pulmonary valve, achieves the same leaflet opening and closing mode as surgical bovine pericardial bioprosthetic valves. In vitro hemodynamic and accelerated fatigue testing shows leaflet symmetry, opening/closing synchrony, and commissural stress are all consistent with surgical bioprosthetic valves.

This confidence stems half from in vitro benchmarking results, and half from over 20 years of clinical validation of the same materials and anti-calcification technology used in Balance Medical's surgical bioprosthetic valves. The company positions the product as "the industry's first all-comer transcatheter pulmonary valve with evidence of durability."

Two Decades of Bioprosthetic Valve Development: Three Innovation Approvals

The ability to tackle challenging procedures like "all-comer" rests on Balance Medical's 20-year commitment to bioprosthetic valves. Founded by Jin Lei, a pioneer of artificial bioprosthetic valves in China, the company's surgical bovine pericardial bioprosthetic valve has been on the market for over 20 years, with anti-calcification and durability supported by large-group long-term follow-up data. The pulmonary valve uses the exact same materials and anti-calcification technology.

The company's commercial resilience is evident in its recently released annual report. In 2025, revenue reached 620 million RMB (approximately $86 million USD), up 23.57% year-over-year. Net profit was 194 million RMB (approximately $27 million USD), up 32.28%. R&D expenses totaled 155 million RMB, representing 25.05% of revenue. Despite dual pressure from valve volume-based procurement and TAVR competition, revenue has continued its growth trajectory maintained since 2016.

This marks Balance Medical's third NMPA innovative channel approval for interventional valve products—the previous two were for transcatheter aortic valves and transcatheter valve-in-valve. Combined with the previously launched right ventricular outflow tract and pulmonary valve repair/reconstruction series (valved patches), Balance Medical is accomplishing something no one else has: full lifecycle management of pulmonary valves for complex congenital heart disease patients. Repair and reconstruction first, minimally invasive replacement after degeneration, and valve-in-valve continuation in the future.

Venus Medical Goes Deep, Balance Medical Opens New Territory: Two Players in Different Lanes

Placing Balance Medical in China's TPVR landscape reveals a clear picture. This is a market with "the only completely domestically produced products globally"—none of Medtronic or Edwards' pulmonary valves have entered China. Venus Medical's VenusP-Valve dominated the transfemoral approach alone for four years (July 2022 to October 2026). Balance Medical entered in October 2026, with Mindy Topface also under registration review.

Venus Medical's four-year track record deserves acknowledgment. China registration study 10-year follow-up shows cumulative mortality of only 3.64%, with no new deaths from year 1 to 10. The product has been approved in over 50 countries. Venus Medical demonstrated with the transfemoral approach that "minimally invasive valve replacement" is a viable path.

But Balance Medical and Venus Medical are not fighting the same battle. Venus Medical serves patients with suitable pulmonary artery morphology—direct transfemoral implantation when anatomy fits. Balance Medical serves those excluded by the transfemoral pathway—patients with super-large dilation, complex pulmonary artery anatomy. Reshape first, then implant, turning the impossible into possible.

The two companies are not competing for the same slice of cake; together, they are expanding the pool of "patients eligible for TPVR" closer to full coverage. Venus Medical spent four years proving minimally invasive valve replacement works. Balance Medical, with a single product, demonstrates that minimally invasive is not the only answer.

Demand and Payment: Window Period Dividends

On the demand side, the 300,000 complex congenital heart disease post-surgical adults represent existing stock, with new congenital heart disease surgical children accumulating each year. On the payment side, TPVR has not yet been included in volume-based procurement due to small patient base and few competitors. This is certainty number one: the high-price window period before volume-based procurement and medical insurance inclusion allows early entrants to capture pricing dividends.

Certainty number two: next door, TAVR has been compressed from over 300,000 RMB (approximately $42,000 USD) to around 150,000 RMB (approximately $21,000 USD) by volume-based procurement. Valve consumables basically lack provincial medical insurance coverage, with patients paying 80,000-350,000 RMB (approximately $11,000-$49,000 USD) out-of-pocket. How Balance Medical's "reshape + implant" composite procedure will be priced under DRG/DIP, and whether it can enter medical insurance, represents an unavoidable challenge.

Two Certainties, One Uncertainty

For any innovative medical device, approval is just the first step—from "approved" to "scaled," commercialization is the real test. Balance Medical's hurdles are tangible: two certainties and one uncertainty.

Higher procedural barriers are certain—"reshape first" requires open-chest surgery and coordination between interventional cardiology and cardiac surgery teams. Currently only available at major cardiac centers, municipal-level hospitals will struggle to replicate this in the short term. But this barrier is also the source of differentiation: precisely because surgical capability is required, Balance Medical can handle complex anatomy that Venus Medical cannot.

Evidence gaps are certain—in the 38-case cohort, there were 3 intraoperative valve displacements and 1 mild paravalvular leak at 6 months post-operation. Whether the reshaped landing zone remains stable over time requires larger samples and longer follow-up.

The uncertainty lies in "what proportion of patients truly cannot be treated." Balance Medical states existing products accommodate only 20-30%, while Venus Medical claims its product can handle 85%. The two figures differ dramatically. The true proportion awaits third-party data.

But none of this changes one judgment: the first half of China's TPVR competition was about who could deliver minimally invasive; the second half is about who can make more patients "eligible." Venus Medical goes deep within the known patient population. Balance Medical pioneers in uncharted territory. When "full lifecycle management" for 300,000 patients truly becomes a business, there won't be just one winner.